A framework for advancing our understanding of cancer-associated fibroblasts
2020 · Nature reviews. Cancer · 3,554 citations
https://doi.org/10.1038/s41568-019-0238-1
R
Robert G. Maki
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
747
Papers
54.8K
Citations
109
h-index
312
i10-index
Robert G. Maki is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Sarcoma Diagnosis and Treatment & Gastrointestinal Tumor Research and Treatment & Vascular Tumors and Angiosarcomas. The author has an h-index of 109, co-authored 635 publications.
ORCID: 0000-0002-9853-2528Papers by this author
worksEfficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
2012 · The Lancet · 1,392 citations
https://doi.org/10.1016/s0140-6736(12)61857-1
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
2009 · The Lancet · 1,345 citations
https://doi.org/10.1016/s0140-6736(09)60500-6
Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation
2005 · Clinical Cancer Research · 826 citations
https://doi.org/10.1158/1078-0432.ccr-04-2245
The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients
2020 · European Journal of Cancer · 449 citations
https://doi.org/10.1016/j.ejca.2019.11.013
Sorafenib for Advanced and Refractory Desmoid Tumors
2018 · New England Journal of Medicine · 434 citations
https://doi.org/10.1056/nejmoa1805052
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat